Table 2.
Ref. | Year of publication | n | SUV | Response criteria | FDG response time | Cut-off value | FDG response, n (%) | FDG-PET/CT vs RECIST | PFS | OS |
Riely et al[20] | 2007 | 13 | Max | EORTC | 21 d | 15% | PR 6 (46) SD 7 (54) | |||
Aukema et al[21] | 2010 | 22 | Max | EORTC | 7 d | 25% | PR 6 (26) SD 16 (70) PD 1 (4) | |||
Mileshkin et al[11] | 2011 | 51 | Max | EORTC | 14 d | 15% | PR 13 (26) SD 17 (33) PD 21 (41) | FDG PR: PR 4 SD 7 PD 2 FDG SD: PR 0 SD 12 PD 5 FDG PD: PR 0 SD 7 PD 14 | R 5.5 mo NR 2.5 mo | R 11.6 mo NR 7.6 mo |
Zander et al[22] | 2011 | 34 | Peak | EORTC | 7 d | 30% | PR 8 (24) SD/PD 26 (76) | FDG PR: PR/SD 6 PD 2 FDG SD/PD: PR/SD 5 PD 21 | R 7.8 mo NR 1.5 mo | R 16.1mo NR 3.4mo |
Benz et al[23] | 2011 | 22 | Max | PRECIST | 14 d | 30% | PR 6 (27) SD 7 (32) PD 9 (41) | R 11.1 mo NR 2.4 mo | R 16.4 mo NR 14.7 mo | |
Takahashi et al[25] | 2012 | 20 | Max | EORTC | 2 d | 25% | PR 10 (50) SD 8 (40) PD 2 (10) | FDG PR: PR 8 SD 2 PD 0 FDG SD: PR 2 SD 5 PD 1 FDG PD: PR 0 SD 1 PD 1 | R 10.4 mo NR 1.7 mo |
FDG: [18F]-fluorodeoxyglucose positron emission tomography acquired together with low dose computed tomography; RECIST: Response Evaluation Criteria in Solid Tumors; PFS: Progression free survival; EORTC: European Organization for Research and Treatment of Cancer.